Caris Life Sciences (CAI) Cost of Revenue (2024 - 2026)

Caris Life Sciences' Cost of Revenue history runs 3 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• On a quarterly basis, Cost of Revenue fell 96.81% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $388.9 million, a 218.66% increase from a year earlier, with the FY2025 full-year figure at $262.4 million, up 2421.9% from the prior year.
• Cost of Revenue fell to $1.9 million in Q1 2026 per CAI's latest filing, from $254.7 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $254.7 million in Q4 2025 and bottomed at $1.9 million in Q1 2026.
• The 3-year median for Cost of Revenue is $57.9 million (2024), against an average of $63.9 million.
• Across the five-year window, Cost of Revenue jumped 7680.48% in 2025 and plunged 96.81% in 2026, its largest moves.
• Year by year, Cost of Revenue stood at $3.3 million in 2024, then soared by 7680.48% to $254.7 million in 2025, then plunged by 99.24% to $1.9 million in 2026.
• Per Business Quant, the three latest CAI Cost of Revenue figures stand at $1.9 million (Q1 2026), $254.7 million (Q4 2025), and $67.0 million (Q3 2025).